ZLDPF Zealand Pharma A/S

Zealand Pharma convenes its Annual General Meeting 2023

Zealand Pharma convenes its Annual General Meeting 2023

Company Announcement – No. 2 / 2023

Zealand convenes its Annual General Meeting 2023



 



Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").
 
The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:
 
Wednesday, March 29 2023 at 3:00 pm (CEST)



 
The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting).
 
The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Søborg. 
 
Please find further information in the accompanying attachment.

Attachment



EN
02/03/2023

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Transactions in Zealand Pharma shares and/or related securities by per...

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...

11h / 53m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma CMD key takeaways

Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...

ZLDPF ZEALAND PHARMA A/S
12/12/25 December 12, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma increases its share capital as a result of the exercise...

Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...

December 11, 2025 1 EN
Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
XIOR Xior Student Ho...
IBAB Ion Beam Applic... ... (+9)

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

XIOR XIOR STUDENT HOUSING N.V.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
ZLDPF ZEALAND PHARMA A/S
ONTEX ONTEX GROUP N.V.
ARG ARGAN SA
AKZA AKZO NOBEL N.V.
SEQUA SEQUANA MEDICAL
DEME DEME GROUP NV
12/11/25 December 11, 2025 1 EN
Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...

Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...

ZLDPF ZEALAND PHARMA A/S
12/11/25 December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch